Cancer 2001: Vol 92 Index

41 Pages·2001·10.1 MB·English

Subject Index—Volume 92
No. 1, July 1, pp. 1-206 No. 7, October 1, pp. 1745-1998
No. 2, July 15, pp. 207-452 No. 8, October 15, pp. 1999-2234
No. 3, August 1, pp. 453-712 No. 9, November 1, pp. 2235-2492
No. 4, August 15, pp. 713-968 No. 10, November 15, pp. 2493-2732
No. 4, August 15, Supplement, pp. 969-1058 No. 11, December 1, pp. 2733-2964
No. 5, September 1, pp. 1059-1348 No. 12, December 15, pp. 2965-3170
No. 6, September 15, pp. 1349-1656
No. 6, September 15, Supplement, pp. 1657-
1744
A Alcohol use/abuse
breast cancer risk and, familial factors
\BI-007, intraarterial infusion of, for squamous cell car- in unresectable lung cancer, 2609
cinoma, 2592 \lkylating agents, gemcitabine as modulati
ACE inhibitors, in cancer prevention, 2462 194
Acidosis, lactic in hematologic cancers, 2237 \llogeneic blood transfusion, in esophageal
c
Acquired immunodeficiency syndrome. See Human im- nosis and, 1913
munodeficiency virus infection \lpha-fetoprotein, as prognostic factor
Activity and exercise lar carcinoma treated with pe!
breast cancer risk and, 1638 nol injection, 126
in fatigue management, 988, 1689, 1699 \lternative therapies, for fatigue
Acute leukemia. See Leukemia \lveolar rhabdomyosarcoma, neonatal
Adenomatous polyposis coli, hepatocellular carcinoma brain metastases, 1613
in, APC inactivation and, 332 American Indians, breast cancer hormone 1
\dolescents. See also Children in, tumor characteristics and
bone tumors in, rehabilitation for, 1013 \mifostine
\drenal tumors, menin in, 1393 ith cisplatin, for breast cat
Adrenocortical cance twice-daily, for refractory
clinical outcome in, 1113 erratum
1-1,dichlorodiphenildichloroethane in, prognosis and \mputation
1385 Amyloid A, it
Adriamycin. See Doxorubicin
Advance directives, predictors of survival after CPR \nal cancel
inguinal node metastases in
1905
intraarterial polyoxyethylated castor
African Americans
for, 2592
breast cancer hormone receptor status in, tumor char
Analgesics. See Pain
acteristics and, 37
Anal gland cancer, 2045
comorbid illness and complications in hysterectomy
\nastrozole
for endometrial carcinoma in, 950
for breast cancer, vs. tamoxifen, 2247
mammography in, recommendations for, 1299 for prostate cancer, 2095
prostate cancer in \ndrogen biosynthesis, genetic polymorphisms affecti
genetic polymorphisms affecting androgen biosyn prostate cancer risk and, 1130
thesis and, 1130 Androgen blockade, for prostate cance!
quality of life and, 1451 mortality trends and, 2309
screening for, 2673 pamidronate after, 1444
AIDS. See Human immunodeficiency virus infection Androgen receptor CAG repeat, in endometrial cance!
Alanine aminotransferase, as prognostic factor, for hep Israeli Jews, 1190
atocellular carcinoma treated with percutaneous Androgen receptor gene, short tandem repeat polymot
ethanol injection, 126 phism linkage to, in prostate cancer, 2603
bmiv CANCER December 15, 2001 / Volume 92 / Number 12
Androgen receptor gene CAG repeat polymorphism, in in mature vs. immature mediastinal teratomas, 1798
prostate cancer, in Australia, 941 2-methoxyestradiol-induced capsase activation and, in
Anemia, fatigue and, 1678, 1684, 1719 gastric cancer, 500
Angiogenesis in nonsmall cell lung cancer, y-glutamyl cysteine syn-
in breast cancer thetase in, 2911
monocyte chemoattractant protein-1 in, 1085 in ovarian cancer, cyclin-dependent kinase inhibitors
tumor progression and, 249 and, 1177
in colorectal cancer, angiopoietin-1/2 and, 1138 in prostate cancer, capsases in priming for, 2297
in endometrial cancer, 2569 in pulmonary artery sarcoma, 1237
in head and neck cancer, thalidomide inhibition of, survivin and, 271
2364 \ppendiceal carcinoids, incidence trends and risk factors
in leiomyosarcoma, vitaxin inhibition of, 1347 (letter) for, 2204
in nonsmall cell lung cancer, prognosis and, 2648 \ra-C. See Cytarabine
in oligodendrogliomas, hypoxia-inducible factor-ia Arm, lymphedema of. See Lymphedema
and, 165 \romatase inhibitors, for prostate cancer, 2095
in pancreatic cancer, 1788 Ashkenazi Jews
vascular endothelial growth factor and BRCAI1/2 and APC founder mutations in, frequency of,
in endometrial cancer, 2569 in Australia, 440
in esophageal cancer, 663 BRCA1/2 founder mutations in, genetic testing for, ed-
in head and neck cancer, nodal metastasis and, 556 ucational materials on, 932
inhibitors of, for acute myelogenous leukemia, 1059 \sian-Americans, breast cancer hormone receptor status
in, tumor characteristics and, 37
in nonsmall cell lung cancer, 2628
\spartate aminotransferase, as prognostic factor, for hep-
in pancreatic cancer, 488, 1788
atocellular carcinoma treated with percutaneous
Angiogenesis inhibitors
ethanol injection, 126
thalidomide as, in head and neck cancer, 2364
\stroglioma, MIB-1 labeling index for, prognosis and,
vitaxin as, in leiomyosarcoma, 1347 (letter)
2720
\ngiopoietin-1/2, colorectal cancer and, 1138
\taxia-telangiectasia, ATM mutations in, breast cancer
Angiosarcoma, after radiotherapy, for breast cancer, 172
and, 479
\ngiotensin-converting enzyme inhibitors, in cancer pre-
Australia
vention, 2462
\shkenazi Jews in, frequency of BRCAI/2 and AP¢
Annexin II, overexpression of, stromal tenascin-C over-
founder mutations in, 440
expression and, in colorectal cancer, 1419
prostate cancer in, androgen receptor gene CAG repeat
Anorexia, neuropeptide Y, leptin and cholecystokinin 8
polymorphism in, 941
and, 629
\xillary node dissection, in breast cancer, lymphedema
Anthracyclines, for acute myelogenous leukemia, 1059
and, 1368
Antiandrogen therapy, for prostate cancer, pamidronate
\zoospermia, postchemotherapy, testicular sperm ex-
after, 1444
traction with intracytoplasmic sperm injection
\ntiangiogenesis agents
in, 1632
thalidomide as, in head and neck cancer, 2364
\ZT, chemotherapy and, for testicular germ cell tumors
vitaxin as, in leiomyosarcoma, 1347 (letter
in HIV infection, 1460
Anti-CD33 monoclonal antibodies, for acute myeloge-
nous leukemia, 1059
Antidepressants, for fatigue, 1714 B
Antioxidants, ovariai: cancer risk and, 2318 Bacteremia, risk factors for, in children with febrile neu-
Antiretroviral therapy, chemotherapy and, for testicular tropenia, 909
germ cell tumors in HIV infection, 1460 Bandages, for lymphedema, 980
Anxiety disorders, in unresectable lung cancer, 2609 Basal cell carcinoma
\ortic lymphadenectomy, in elderly, 2562 likelihood of participation in preventive behaviors for,
APC 1315
founder mutations in, in Australian Ashkenazi Jews, truncal, susceptibility to, 354
140 Basic fibroblast growth factor, in pancreatic cancer, 1788
inactivation of, hepatocellular carcinoma in familial Bax, in pulmonary artery sarcoma, 1237
adenomatous polyposis coli and, 332 BAY 59-8862 (taxane analog), for glioma, 3085
\poptosis B-cell chronic lymphocytic leukemia, prognosis and, 713
BCL2 and, in pancreatic cancer, 1122 BCL2, in pancreatic cancer metastasis, 1122
in hepatocarcinogenesis, 2733 Bel-2, in pulmonary artery sarcoma, 1237
in HHV-8-associated malignancies, p53 and LANA in, Bcl-2 inhibitors, for acute myelogenous leukemia, 1059
3076 Benzopyrones, for lymphedema, 980
Subject Index—Volume 92 bmv
Benzydamine hydrochloride, prophylactic, for radiation- Brachytherapy. See also Radiation therap
induced oral mucositis. 875 endobronchial. { i erie Oia ad . :
iInaduced Oral MUCOSIUS, o/o9 naovroncnhnial, fo! eooroncnk {umors, Massive
DDDI; Opsy |h emoptysis after, 2623 )
prostate, Suspicious for Malignancy, predictive value for prostate cancer
of, 524 long-term results of, 2084
sent ¢ quality of life afte 15]
in ncel Brain metastasis
ifter preoperative chemotherapy, 1080 in cancer, al reoperative chemo!
treatment implicationosf , 1769 diotherapy
in papillary thyroid cancer, 2868 1 neonatal alveol: Sarco ;
Blacks. See Afri. can .A mericans rroehhoaahbiliiltiattianyt:i on for, 1029)
Bladder cancer in rhabdomyosarcoma, routine Drain scans for at diag
c. ycil¢o ox‘ ygenase-< ) iInn yy invas ness and ; surviva n- osis; 1a?s1
and, t8é ) I
FGFR3 in, thanatophcric dysplasia mutationisn , 2555 ep! of, 1 erma
fol] low-up in, n analy] sis vs. cystoscopy il otem
14
.
2 fol 5
t a ( 2 7
il mat s {to }
‘ a l ASLIRK i C >
tion with, 304
\ustralia, 440
Bone marrow metastasis »(
in 1D reast cancer, Maspi: n as Marker for, 2050 : ounled ejr mutations in, in Ashk1 en ews
o“ccultc. uiinn l Dhrlree a,st f Cnacnecre r, yoOporNoOgsnSo)si s amnidnd,. 4466 1 Australia. 440
Bone marrow transplantation , i
ven ing [o eCauce or ¢ S Tt +
for acute myelogenous leukemia, 1059 in ovarian cancer, 787
illness intrusiveness after, 3147 ¢ '
7 yste> oporosis alftteerr, 1p ath1oOgSeGenNeessIiss ofO,f . 224411 9 fibroadenoma with; a sf. breas re .
pediatric, chemotherapy-induced stomatitis in, TRAUN | riegtiadst asis to, 2O2R5 G
Ss for, 6564 7
rehabilitation after, 998 RB)
Bone metastasis 6
in breast cancer, surgery for, 257 !
in prostate Cancel rs affecting, 2
predictors of occult spinal cord compression in, 303
urinary cal 1 excretion in monitoring of, 1468 1, 249
receptor activator of nuclear factor-AB ligand 160
rehabilitation and, 1020 edem d, 136
R > th al sree hes ensues
pone tumors. see also specifi ype ) i (
amputation for, rehabilitation for, 1013
ifosfamide with radiotherapy for, toxicity of, 1550
limb salvage in, rehabilitation for, 1013 founder mutations in, in Ashkenazi Jews
5
osteoprotegerin for, 460 in Australia, 440
bmvi CANCER December 15, 2001 / Volume 92 / Number 12
genetic testing for, educational materials for, 44{ 0
prognostic value of, in Japan, 54
) Ovarian cancer, 2837
breast conservation therapy for, in elderly, 1092
( achexla
cathepsin D in, prognosis and, 2957 cytokines and, 1684
chemotherapy response in, -Tc-MIBI scintigraphy fatigue and, 167 78, 1684
in prediction of, 232 muscle wasting In, 1669
cisplatin with amifostine for, 251 alcium, urinary, in monitoring of bone metastases, in
cumulative incidence of, 2220 rostate cancer, 1468
( juctal in situ, mastectomy for, vs. breast-conserving alpain, in mer! in proteolysis, in meningiomas, 26(
Res
therapy, 223 attitudes toward preventive strategies for hered
ec rly-stage adjuvant therapy for, 1354 itary breast/ovarian cancer in 959
estrog§e n/ Ip rogesterone status in, race/ethnicity and, 37 ancel
HER-2 neu DNA amplification in, 2965 \CE inhibitor protective effect for, 2462
hereditary, preventive strategies for, attitudes toward advanced, conditional median survival in, 2211
in English, French and Canadian women, 959 ( ancer cachexia
inflammatory, paclitaxel for, | ) cytokines and, 16
lobular in situ, E-cadherin in, risk of subsequent cancel fatigur1e1e Q and {
and muscie wasting 1n,
lymphedema in ancer palin
axillary node dissection and, 1368 atigue and, 1678, 1684
management of, 980 fentanyl for, conversion from IV to transdermal admin
risk factors for, 17 istration O! 3056
ifter s iphadenectomy, 7 ntravenous methadone tO 1919
it 20-ve follo ip 568 ne t of
,m itit ox. ant} rone} » wviartithh cyw¢e l ophoP sphlaam idied fOr, < ) \é I dvanced cance! U49
conversion from IV to transdermal fentanyl in, 305
monocyte lé yattractant protein-! in, 1085
MRI in, with 3D fat suppression, 471] ) ¢ DH tatiol
occult Done Marrow Metastases 1n, prognosis and, 4 I 1idvanced disease ( J
older women, chemotherapy for, 730 amputatiol lS
as 5 l > >/ Lit pone n WWt ranspiantation, YX
radalt equ t10n [fol USO
\one metastasis and, 1020
raqaa iotthm erapyr [fo
tO entrai nervous systen umors, 1029
soit tissue sarcoma altel 2
tfhryer oid cancer after, aS141 1] igue and, 988. See also itigue
future directions in, 975
risk of
history of, 970
with fibroadenoma with atyq
integration of into medical care, 1055
physical activity and, 1638
for limb salvage patients, 1013
screening for, targeted subpopulations for, 1299
lymphedema and, 980
sentinel lymphadenectomy for, lymphedema after, 748
palliative care and, 1049
sentinel node biopsy in
sexuality, 1008
positive, treatment implications of, !769
ancer-related fatigue. See Fatigue
after preoperative chemotherapy, 1980
ancer survivorship research, tumor registries in, 1305
sentinel node micrometastases in, 137
andidiasis, chronic disseminated, in acute leukemia
skeletal metastasis in, surgery for, 257
, 1349
stromelysin-3 and, prognosis and, 2957
apecitabine, for taxane-refractory/failing breast cance!
tamoxifen-treated, risk of endometrial polyps in, 1759
115] apsase(s
taxane-refractory/ failing, capecitabine for, 1759 in apoptosis priming, for prostate cancer, 2297
urokinase in, prognosis and, 2957 2-methoxyestradiol-induced activation of, in gastric
vinorelbine for, in salvage therapy, 2267 cancer, 500
in women with thyroid cancer, 225 arbon dye mapping, of sentinel nodes, in melanoma,
in younger women Dao
body mass index and prognosis in, 720) arboplatin
poor prognosis in, 2523 vs. cyclophosphamide plus vincristine, for small cell
surgery and chemotherapy for, quality of life and, lung cancer, 601
1288 with liposomal doxorubicin, for cervical cancer, 2327
Bronchioloalveolar cancer. See also Lung cancer for nonsmall cell lung cancer, with/without radiother-
DNA mismatch repair genes in, 2898 apy, 2142
i
Subject Index—Volume 92 bmvii
viftohr head and neck Ca er, Z B > DNnA nephamrpolbilfaisctaotimoan,. inp robgrneoass is andce,r , 312926
yr noinnds n , Ce ng cance perto stat Ci | -m etaCar ice S fter high-dose yperative
t Da litax 1 C I ) [ lothe ip bi
ru yu i, [0 ava Sg } us é I uveoiar rhabdon )
non i, ry ) r¢ 1029
n ins eqt ) ¢ n) if tioI n nsee AKIOE OG | 9 | e os2a]r col } yu ) C c ft
ice-dall imMirost ( itn O ict ped tri ra } t f
rcl bryonk n portal and perip! O staging system fo! 7
blood Wore ti CalNce ) ONnOSIS n Ogiolt S respons |
arCil 14d tumors d 13
ippée ndiceal I } ( ( is rie S fac ! I 0 IOgIC S ) YT: ) g >
roregut agi splat 1 etopo l¢ 500
nciden { > a SK I LO O 22U ] t piatl l Dp 5
if . | ) } ron ( f ( ,
sect ( pe ) € { Sp © Ste
T y t t S
( ) S , € )
i i t
Cate
I ) O ( [ Dla ”
Lud n/t ane ) ( J ous K
Cathepsu SIS 1) 1d ) st ¢ ¢ prog SIS 5 h ge eda agse nts l ( ( S I o
Catheters, standa 1-ended vs. Gros n¢ i 4
CD44 1¢ S 0 rt¢ racvtoplas€ mic estiscp erm ir spe ( l ) \
sIno lupbrleen eosperluams, it NSm phocyt) ic leuke1 indadrerro w cancteo xicity2 99 of, 2419
prognosis r breast cancer, 2247. 2508. 2517
CD44 variant 6, i I ylorectal cane ea 54
CD95, in 2h5ep3pe9ar tiopcheelrlaull arb loocda rcivsn. omcay,t otox2i1c3 6 lymphocytes, in sn alvoalgde'e,ct -MI2B2I6 7 scintigraphy in predi 222
Cell lines, prostate cancer, apoptosis priming for, cap n youn women, quality of lif 288
Central lshyaemsmepash taotilinoc, gi2c2i9 r7r raedcioatvieorny, affotre r, fol1l0i7c4u lar lymphoma eyrn trCaals tslvheeonmnoaguns dcpiaotsrheetatsse er ,f orfo,r d,i sseta1as2en0,d 4a rd6 70o pen-ended vs. Gro
Central nervous system tumors. See also specific types and or cervical cancer, 2327
pediatrics,it es medical and neurocogn late effects i coOl n for 135
2709 for nonsmall cell lung cancer, 146
rehabilitation for, 1029 performance status and, 2639
Central venous ports, standard open-ended vs. Groshong topotecan and gemcitabine for, 414
catheter for, 1204 dose-escalated CHOP, for diffuse lymphoma, 20 |a
bmviii CANCER December 15, 2001 / Volume 92 / Number 12
for esophageal cancer, in trimodality therapy, 1273 ( ‘hest computed tomography, in staging of Tl extremity
for esophageal/ gastroesophageal junction cancer, fol- soft tissue sarcomas, 863
lowed by chemoradiation and surgery, 279 (\ hildren. See also spI ecif: ic cancers of childhood, e.gé ., Leu
for fibromatosis, 1259 kemia
for glioma, 1936 CNS tumors in, medical and neurocognitive late effects
for head and neck cancer, 326, 814, 2334, 2364 in, 2709
hepatic artery-infusion, for colorectal liver metastases, febrile neutropenia in, risk factors for bacteremia in,
2746 909
for hepatic lymphoma, 2023 hemangiopericytoma in, 2692
for hepatic metastases, from germ cell tumors, 578 Hodgkin’s disease in, Epstein-Barr virus and, in China,
hepatitis B virus reactivation and, 2927 1621]
for Hodgkin's disease, with large mediastinal involve non-Hodgkin's lymphoma in, second malignancy after,
ment, 453 1959
hyperthermic pleural perfusion with, 2197 osteosarcoma in, HER-2/neu oncogene amplification
for inflammatory breast cancer, 1775 in, 677
infusional, for HIV-related non-Hodgkin's lymphoma, refractory cancer in, twice-daily amifostine for, 914,
200 3170 (erratum)
intraperitoneal, for peritoneal carcinomatosis, from solid tumors in, increasing incidence of, in England,
colorectal cancer, 71 1967
for large cell lung cancer, 1108 stem cell transplant in, chemotherapy-induced stoma
for lung cancer, 2158 titis in, TRAUMEEL S for, 684
for maxillary sinus cancer, 1495 upper respiratory tract cancer in, chromosomal trans-
for metastatic melanoma, 609 location 15;19 and, 1195
for miillerian tumors, 1156 ( hina
for myelodysplastic syndrome, 1999 nasopharyngeal cancer in, radiotherapy for, 2126
myelotoxicity of, pathogenesis of, 2419 pediatric Hodgkin's disease in, Epstein-Barr virus and,
for neuroendocrine tumors, 1101 1621]
for nonsmall cell lung cancer, 146, 595, 814, 2391 ( hinese-Americans, breast cancer hormone receptor sta-
performance status and, 2639 tus in, tumor characteristics and, 37
in second-line therapy, 2902 holangiocarcinoma, intrahepatic mass-forming, staging
for ovarian cancer, 168 56 of, 2374
with tumor debulking, 3585 holecystokinin 8, in cancer-associated anorexia, 629
for pancreatic cancer, 569 "HOP regimen
re~
for pediatric CNS tumors, medical and neurocognitive dose-escalated, for diffuse lymphoma, 207
late effects of, 2709 for primary hepatic lymphoma, 2023
for pharyngolaryngeal cancer, 1504 hromosomal abnormalities, in papillary thyroid cancer,
}
for pleural mesothelioma, 650 529
prophylactic, for hereditary breast/ovarian cancer, at- ‘-hromosomal translocation 15;19, pediatric upper respi
titudes toward in English, French and Canadian ratory tract cancer and, 1195
women, 959 hromosome 22 loss/gains, in meningioma, tumor ag-
for prostate cancer, 2435 gressiveness and, 377
with radiotherapy. See Chemoradiotherapy Chronic leukemia. See Leukemia
for renal cell carcinoma, 519 ~ igarette smoking
resistance to, PSC 833 : for, 1577 K-ras mutation and, in lung cancer, 15257
for retinoblastoma, resistance to, 2933 in unresectable lung cancer, 2609
for rhabdomyosarcoma of parotid region, 3135 isplatin
for small cell lung cancer, 601 with amifostine, for breast cancer, 2517
somatostatin receptor—targeted, for ovarian cancer, with doxorubicin and interferon -2b, for pleural me
1168 sothelioma, 650
stomatitis in, homeopathic medication (TRAUMEEL S$ for head and neck cancer, 814
for, in children undergoing stem cell transplant, hyperthermic pleural perfusion with, 2197
684 for neuroendocrine tumors, 1101
for testicular germ cell tumors, in HIV infection, anti- for nonsmall cell lung cancer
retroviral therapy and, 1460 with pemetrexed disodium, 595
twice-daily amifostine with, for refractory pediatric performance status and, 2639
cancers, 914, 3170 (erratum) for ovarian cancer, 1856
vasoactive intestinal peptide analog in, for enhanced for pancreatic cancer, 569
chemosensitivity and reduced toxicity, 2172 for pharyngolaryngeal cancer, 1504
Subject Index—Volume 92 bmix
Ccl-koinVtaa lsiotmayuc,tt tatciutuvhmiimeeon oo mr,nroi i ssnn ettner1assI8annti 0didt7un i cafvtlaui amrLt«il tlIy pi ye c aprtaaiipwnaiidd tle l hpar iareycngs d-ama;ules contegrtld oou iscwnaiItttn,oehox s,iU tc 6i1Sf5n oi7at;v l,p aenn2c1shr7tae2ran otcmieacdl CCCoOorieXutnl -miFca24t r Er Oiasnnsta,ien tdr,io ofinodarsi ln lhylcemoearpl dlh feacdataeinrgcdmuj ae ,, n ec1k97 8104d ys pia
CCo-gmneitthivieo no5ri fandduaeend ec tsilpoi ooLsnOni M tr<o i,n preom Sinsos iSoInS tomography, tor [oy
fIna ticghuiel dahnodo, d 98C; N))S 1] 6t9u4 I mo! Vivors, 2709
CCoollmrooaennth r aibxccia alrnic2mc t2eea0rItt4.na i oloilndo s§ p,€ r€fi o TtYa..ri 1s ¢ osI iendeCae onslceeoC- ra9ne ccetirna , l | vs.c ; aiilnni cceerr]e ct factors fo C(_ rraanOnriin oiaCat Nhlai icglinditahrri-leorr nnai, ds pikw aritoltiaashot,cte nuh teens3 ee0us4|r5 y hIco r |e
Colony-st for velogenous euke U-terminal Src kinase act i ppt
CCoolloorneyc taslt imcta ncel InN OV Cancer, 2837 ( COussC aanrccmeeor m, a,as t6 asi1s6,1 3 } lé ita
aaanndgnvleaoxnpiocnieee dxt,piI nrI -e1ocs/vos2eni rdoeinaxt ipnoradnne,d s, s ui o11mn14e 3]d89i ian n strsoumravli val tenian sci2 n-¢ (C yc li‘ OOCxOcXUveSgpe elelnn adtspueremon-olt2ir fse r kiSin?t¢ai osne S KI al jy n( ibi] toOrpst os
circulating tumor cells in prognosis and, 12 } and, in head and eck dys
ICLIVITY | Staging ransSiitvieonneasls caenld] Carscu} inoma ind i
) Senase-2 inhibitors. f i y
Ciopnosphamide
) nd intrape fSeu s SCaal,l atefodr, HIfoVr- re1l aItTUeS,E mp 1
rPpparrpdeeoioovopp teehrreaarttaiivpveye ( rcafhi dteeiml oot;h enearulita drnioa pStriheoi nlO ri,K ci ntsoa tsoe¢ ckdhtol( ilgmue cyt\I e]a ndi ndal of : T} I tfO)dx VaSnD epat)s iticc fso r npblIrT eas 2
ind +4 ) sting S
Ssttaaggee [II]] che IDAnIoVtihsei o ipy I, for2 /54D at It Sele O }
suDsite-sSpeaesc ific ing ce ra CG disease stage OLE O
tumor budding in, CD44 ariant ( 1 nucle ( FR n bladde
nir ' »2Q Ifa-Spal ‘
( OuMrpeatrhra tiiv-eS pargienngo mi¢ c stehcvtbroimdyi IaOt! ior vome 1D t 1[0 US DOlSe uk i )
Ol esophageal cance] 2769
Of postirradiation sarcon a, 1993
CCoommpprleesmseinotna ryg armelnetdsi.ci { ) S iS { Cc ( adeno } >
Computed tomography IK Hes 2
lor brain metastasis, in Ole a 104
chest, in Staging of T] las ( | S al ( ce ron Ing ¢\ . K »S
vs. 18-f luoro 2-deoxygluc ose PI \ for, 2016
cancer, 434 Sine iOINOSIdE
CCCooonnnIjssd ne aintnltigu,oun ngia nflioc rta ynS,cpu eerrdv iilaveta5u,rl k,ier cem ejinn raNi e nasgeda,avn rdac n1hi c5 l3e ydfom rp 3c0h;5l a oenmuckeaer sm,i aa a,nd 2 ?i, ]6]9 I] ( Ot{ r OxpInarcc vi em atlér Oyydm y]p shphloeCalpcOsayZttetiiEeccN s OU S Slvyrnamdsp rfh|¢ ooani;nIt xiegne na, 202it 1 tOce!
bmx CANCER December 15, 2001 / Volume 92 / Number 12
DDDDD aaeecufclcaoniiorrpot nboardaasbuicozibutminitainekelcoe,e ,in, m ni imnf aywogf,rieo , trl ha7o c mrguceeethylneata obanuirmolasyibm teiaanll,teoe i,ugo ken2e f1nom9orfi0 uoa ras.,c uStle1eee0 u5k9Cm eaymneiclaeo,rg en1r0eo5hu9as bi lilteua - DDDruyfvcusoatgrpsa iolasa aoscbftttuci iscacbtvehr troe,eicce snmieasoolniiusdslnneotu uet m-llenuacaesssnro tsair in,rten sciicasneovlae arm isrcvsa tctpii,yiatpen unbprg olte waimenoindf aetl de,odh l p eburlrartnea2aneyagp7spsad y3ttelu,3ic, o c cagenp 2dc5m3 elw3a rei ss,tttaio hxno,eid n2cc,s6tif 0oto9ryim1 , n5 ye,5 n26ih1 n7af o2nrh ,ce epdaVS- .
tion
E
Depfairafntet eisurgs nuireloe unsna egnc dt,ca abnl1c6ee8 r4 f,lo urs nu1grh6 g9ee4pcr aaynt,co ecrep,lh lyus2li6ac0ri9 a nc arscuippnoormta , an3d0,9 3 1926 EEa-rcilany d hlLeourbniugnlqa ureC natcn caercrca nicneoArcm tai aonn di,n Prs7oi3jte8uc t,o f 1b5r3e ast, risk of subse-
DDDeeesxxfatemrreortaihomaxpashmoeintneae,m, i nfeor, faftoirg ufea,t ig1u7e1,4 1714 in adrenocortical E-cina dphreorsitntai tc eg teontcaaeln cemgrua,ts attrpierocontgson,mo ys,ia ss 1i8an]n ddi,c at2i7o8n6 for prophylac
}-] Dichlocraoncdeirp,h enpirlodgincohsilso roaentdh,a n1e3,8 5 Economic factors, in prostate cancer, 2796
DDiieceto avtnahrcyielar-n-m raceelrcle,aa anttc2eee2d,r9 7 fiaannt dia,gp uoe2 p3t1ao8nsd i,s 98p8r iming, for prostate can- EEeeddlliuFFt-c-o4a4rEtE-,i/i o2nCna-a,fcOh loXi u-ein2fndm ’easbrta re norrdinme,acup lothsriai,tnto ,il hoooen2anas2l d5,v 9 eg oaeilnnnae drt A iscnh veskc.e kten ssatdqziyiuns gap,ml Jaoeswufisosar,, 9Bc91eR2¢l38 C9l 8 A8I l/un2g
DDiissasbielmiitnya.p teerSdei et opnCeeariin tcoeinnre, alVS r.e haiadnb eipnleoirtmiauttcioionnneo asli sm,u cipnsoeuusd omcayrxcoinmoa- eEllEas-t4iGc, ciocnam npscrqeerus,a smio2o1un5s 8 gcaerlml enltusn,g cfaonrc elry, mp8h22e dema, 980
DDiNuAr/etciyctso, kmaeftrooars tiilsn,y mp8f5hl eowd emcayt,o me9t8r0y , in bladder cancer, for Eldbehrreelaayds t ancdo nsneercvka ticaonnc ert heirna, pyc omfoorr,b i1d0i9t2y and survival in,
DYYNNNAAA fmmrieastgr2hmme7yaec8lntu6atrc tarhite oinnocr,nee ,p adiienri nt egpcpertunoilesosmtn,a,o t neai 2nr8 1ycb1 a,rn oacnre2tcr8eh,2r iy0o lpsoraaorlgcvnoeomosali,as r 1ac2na3dn7, ELImpSealAmv imcto esg2tar1,rne 0dan9u c preiha noyradt reiytc e icnb,tl liyaormdnedp,ce hora 2md8mc1ee1an,nre dccai2ttn8o2oim0mo yan s afnofrto,i rg, e2n51,62 29 9f or recul
DNA ploidceyr , 2898 Embofo limzeantiionng iomas, clinicopathologic assessment and
iinn graesntarli c ceclla nccearr,c inpormoag,n ospirso gannods,i s2 9a4 nd, 2280 portal gvreiand,i npgr eaofpteerr,a ti70v1e , in hepatocellular carcinoma,
Docweittahx elci splatin, for nonsmall cell lung cancer, perfor- Embryona2l3 84r habdomyosarcoma, with skin and brain me-
Dowf wioitrnt hoh tl ugvnremig2emna 9sco0uncirs2catec nelaicb bteiairntsn,eete ,a ,t 2ou1rstfd 5ooer8r ra snn,dno ,on npssr2mme6ada3li9llc l t ocrcesell ll ofll uusnnuggr viccvaaannlcc eerra,f, t er22 339C914P ;R EEEnnndddooobccrrroiinnncetem1ha o1sir0tpast1aah,l sne e crsar,mpeb ayars,ta1 si6cic1hv3 fye ottr h uemhproerarmospso,ytp ,att yceis s1i0pc1sl a antctaiefrnrta e,cra ,hn edmo2o b6rer2tt3aool nipctohysi iadlte r enftodur-s,
and, 1905 and, 2309
Doxwoitrhu biccilsiipnol maati,n 6a5n0 d interferon -2b, for pleural mesothe- Endahonymdsertteorrgieeacnlt omrcyeac necpfetorro ,r cCoAmGo rbriedp eati llnien,s s ina nIds raecloim pJleiwcs,a ti1o1n9s0
dgiloenisfmpewufcoi-soisrtiet ohosam ngc2abala0clliil0a, ona rmetba efo,dop ra,ls a 1Ht9fmIi3ooVnr6-,d r udeliflfaoafrttu iescndee gr vlinyacogmanelpn- htHco oamdnfaogcr,ek,r i,n1 2'904s27 3 27l ymphoma, EEnnldudorosoesmm teehtotrrfra iopibf-arm,rosl eoeip staradissar pctliiio ioanltnlacygy ap -dnsrifecn,caen,e cyl ortasr,pocttir resaesokdrc 1g tc1nfio5inaop1,mcnrs tyoioo9t smr5e sai0f n o a rnf,o dro,,1f1 8ia65nn44u 2dtt e armiinonext eigfrecinon-r tpruase3, a teexd-i n
for primary hepatic lymphoma, 2023
Subject Index—Volume 92 bmxi
women <50, clinicopathologic correlates of an Exercise
atomic location in, 2° breast cancer risk and, 1638
Endothelial cancer, vascular endothelial growth facto fatigue nanagement, 988, 1689, 1699
flk-1(KDR) receptor pathway in, 2569 or lymphedema, 980
End-stage care, predictors of survival after CPR in, 1905 EZrin, In Ovarian cancer, 3068
England
attitudes toward preventive Strategies {tor hereditary }
breast/ovarian cancer in, 959
increasing incidence of pediatric solid tumors in, 1967 Facial pre il e cfact
Ependymoma, ovarian, tumor imprint cytology of, 3165
ralopian irethra-sp g tecto
Epidermal growth factor, in ovarian cancer, ezrin and
1864
3068
Familial adenomatous polyposis coli, hepatocellul
Epidermal growth factor recepto1
cinoma in, APC inactivation and, 332
in colon adenocarcinoma, staging and
Farnesyl transferase inhibitors, for acute mvelogenc
in nephroblastoma, prognosis and, 3120
eukemia, 1059
Epithelial cell adhesion molecule, regulation of by tumor
Fas antigen, in peripheral blood vs. cytotoxic lymph
necrosis factor a, 620 cytes, in hepatocellular carcinoma, 2136
Epstein-Barr virus, in pediatric Hodgkin's disease, in
s ligand, serum soluble vlad 287
China, 1621 itigue
Epstein-Barr virus Rta protein, in nasopharyngea
cancel nem ind, 1678, 1684, 17
diagnostic utility of, 1872
assessment of, 1733
Erratum, 3170 biologic basis of, 167%
Esophageal cancer cognitive function and, 988, 1694
allogeneic blood transfusion in prognosis and, 19] cytokines in, 1684
chemotherapy for, followed by chemoradiation and depression and, 1684, 1694
surgery, 279 drug therapy for, 988, 171
comparative genomic hybridization of, 2769 epidemiology of, 1733
lymphatic vessel invasion in, prognosis and, 1 21292982 xercise for, 988, 168° 1699
rising incidence of in white males, demographic varia infection and, 1678, 1684
tions in, 549 interferon-related, 1664
trimodality therapy for, 1273 anagement of 988. 1689. 1699
muscle wasting and, 1669
vascular endothelial growth factor in, 665
I strogen receptor-ts ina tivation, in prostate Cancer, 2076 yverview of, 1657
patient's perspective on, 1662
Estrogen receptor status, in breast cancer, race/ethnici
and, 37 esearch funding fo (37
Estrogen replacement therapy, in sexuality rehabilitatio specialt\ for, 170
1008 sun ind, |oobY b5
Febrile neutropenia, in childre sk rs for
Ethanol injection, for hepatocellular carcinoma
prognostic factors for, 126 iin Yi)
with/without transcatheter arterial ] ch} emoemboliza
conversion from IV to transdermal for, 3056
tion, 1516
travenous methadone substitution f |
Ethnicity. See Race/ethnicity
ertility
Etoposide
naintenance of, in epithelial ovarian cancer, 2412
dose-escalated, for diffuse lymphoma, 207
ulation induction for, after conser f
infusional, for HIV-related non-Hodgkin's
ment of borderline ovarian iors, 32
200
retoprotein, aS prognostic factor or hepatoce!
for neuroendocrine tumors, 1101
carcinoma treated with percutaneous ethar
for primary hepatic lymphoma, 2023
injection, 126
wice-daily amifostine with, fo1 refractory pediatric ’4-Fetoprotein, as prognostic factor, tor hepatoce
cancers, 914, 3170 (erratum carcinoma treated with percutaneous etha
Eukaryotic translation initiation factors 4E and 2a, in injection, 126
bronchioloalveolar vs. squamous cell lung can Fever, fatigue and, 1684
cer, 2158 FGFR3, thanatophoric dysplasia mutations in, in blade
Ewing sarcoma cancer, 2555
ifosfamide with radiotherapy for, toxicity of, 1550 Fibroadenoma with atypia, breast cancer risk and, 3\
insulin-like growth factor type 1 and IGF binding pro- Fibroblast growth factor receptor 3, thanatophoric dy
tein-3 in, prognosis and, 294] plasia mutations in, in bladder cancer, 2555
bmxii CANCER December 15, 2001 / Volume 92 / Number 12
Fibromatosis, advanced aggressive, methotrexate and glucose transporter-1 in, prognosis and, 634
vinblastine for, 1259 immunohistochemically detected nodal micrometasta-
15;19 translocation, pediatric upper respiratory tract can- ses in, prognosis and, 753
cer and, 1195 interleukin-18 in, prognosis and, 2050
FIGO staging system, for cervical cancer, 797 K-ras-2 in, prognosis and, 294
Filipino-Americans, breast cancer hormone receptor sta- lymph node micrometastases in, genetic detection of
ius in, tumor characteristics and, 37 2056
fik-1(KDR) receptor, vascular endothelial growth facto 2-methoxyestradiol-induced caspase-3 activation in
and, in endometrial cancer, 2569 apoptosis and, 500
Flow cytometr MGMT-methylation in, K-ras and, 2760
DNA/cytokeratin, in bladder cancer, for recurrence de- microsatellite instability in, 92
tection, 2811, 2820 mucin in, prognosis and, 1427
in gastric cancer, prognosis and, 294 p53 and p21 Pl in, 1828
in renal cell carcinoma, prognosis and, 2280 prophylactic total gastrectomy for, germline E-cad
Fludarabine herin gene mutations as indication for, 18]
for acute myelogenous leukemia, 1059 S-phase frac ecia a prognosis and, 294
for myelodysplastic syndrome, 1999 Gastroesophageal junction cancer, chemotherapy for
1Q8 -Fluor- o-2) -deox5 yglx}u cose posiitt ron emis; sio; n tomogra. followed by chemoradiation and surgery, 279
phy Gastrointestinal stromal tumors, with urticaria pigmen
vs. Tc tetrofosmin SPECT and CT, in nasopharyn tosa, kit mutation and, 657
geal cancer, 434 GD2 synthase, in neuroblastoma, 924
for head and neck cancer, cost effectiveness of, 2341 Gelatinases, in colon vs. rectal cancer, 2680
for staging in radical radiotherapy candidates in non Gemcitabine
small cell lung cancer, 886
with 5-fluorouracil, for advanced solid tumors, 1567
5-Fluorouracil
ae ms with ifosfamide and doxorubicin, as modulating agent,
for colorectal liver metastases, 2746 194
witithh eggae emceic ittaatbl ine,,e ff or adlvaannccee d soolliidd tumors, [15c6e7o for nonsmatl l es cell lung cancer, 8ii3 0
intraperitoneal yr peritoneal carcinomatosis, from : :
sia ser nope Or pe ew oa with docetaxel, 2391, 2902
col1o re» ctal ] cancer, ~7= 1 . :
: . ‘ : ‘ ; with gemcitabine, 2639
long-term continuous-infusion, with paclitaxel and po ; 1 oR 2
F ; oo : ' performance status and, 2639
carboplatin, for advanced squamous cell carci- A
in sequential combination, 146
noma, 642 Ne ee ee
a ick with paclitaxel, for bladder cancer, 2993
for Maxillary sinus cancer, 1495 : =
: eee for pancreatic cancer, 569
for pharyngolaryngeal cancer, 1504
: se i with topotecan, for advanced tumors, 414
with radiotherapy, for rectal cancer, fatigue and, 1725
ig ae se vasoactive intestinal peptide analog with, for enhanced
olinic acid, for colorectal liver metastases, 746
i; | ‘ | ae lene: ; chemosensitivity and reduced toxicity, 217
ollicular lymphoma, central lymphatic irradiation for
= Gemtuzumab ozogamicin
hematologic recovery after, 1074 y
, aa 5 s = eae for acute myelogenous leukemia, 1059
Foregut carcinoids, cisplatin and etoposide for, 1101
ie ae venoocclusive disease and, 40¢
Fractures, pathologic, rehabilitation and, 1020 : a
Gene expression profiling, for hepatocellular carcinoma,
Frameshift mutations, in ovarian cancer, 2829
395
France, attitudes toward preventive strategies for hered-
a3 rf Genes. See specific genes and gene families
itary breast/ovarian cancer in, 959 Orr ae o = 6 Bea ea hot otras =
Ftora: fur, wit. h uracil4 and 1 leucovorin, for head and neck | Ge; netic pt olymorphpa isms, affecting androg5e n bDiosynthe
i - 29 sis, prostate cancer and, 1130
cancer, 326
Genetic testing, BRCA1/2 founder mutations in Ashkenazi
Jews, educational materials on, 932
G Germany, brain tumors epidemioiogy in, 3155
Gallbladder cancer, hepatic metastasis in, 340 Germ cell tumors
Ganglioneuroblastoma, histopathology and MYCN status hepatic metastasis in, multimodality treatment of, 578
of, 2699 in HIV infection, 1460
Ganglioneuroma, histopathology and MYCN status of, mediastinal teratoma, mature vs. immature, apoptosis
2699 and proliferative activity in, 1798
Gardner syndrome, hepatocellular carcinoma in, APC in testicular, MAGE-A4 in, 2778
activation and, 332 Germline E-cadherin gene mutations, as indication for
Gastrectomy, prophylactic total, germline E-cadherin prophylactic total gastrectomy, 181
gene mutations as indication for, 181 Giant cell tumor of bone
Gastric cancel osteoprotegerin for, 460
DNA aneuploidy in, prognosis and, 294 receptor activator of nuclear factor-KB ligand in, 460